Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.34 -1.1%	$24.72	$22.64 ▼ $53.96	$1.19B	0.77	489,438 shs	393,981 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CDTX Cidara Therapeutics	$21.31 -3.6%	$21.99	$10.14 ▼ $28.42	$267.44M	0.79	88,509 shs	127,800 shs
GPCR Structure Therapeutics	$21.62 +3.1%	$22.89	$13.22 ▼ $49.03	$1.24B	-1.87	850,864 shs	639,625 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-1.42%	-4.87%	+3.02%	-8.08%	-36.83%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+2.70%
CDTX Cidara Therapeutics	-1.38%	-15.55%	-13.33%	-2.86%	+75.54%
GPCR Structure Therapeutics	+1.94%	-3.94%	-16.69%	-7.09%	-56.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.1707 of 5 stars	3.1	1.0	0.0	3.7	2.1	4.2	1.3
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	4.0013 of 5 stars	4.6	2.0	0.0	4.6	1.4	0.0	0.0
GPCR Structure Therapeutics	2.5323 of 5 stars	3.5	2.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	27.60% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.11	Buy	$42.86	101.11% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.50	253.84% Upside

Current Analyst Ratings Breakdown

Latest CDTX, AMPH, CALT, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
6/10/2025	CDTX Cidara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.63	$4.91 per share	5.16	$15.23 per share	1.66
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CDTX Cidara Therapeutics	$1.27M	210.58	N/A	N/A	$14.92 per share	1.43
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	9.18	7.70	6.77	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)

Latest CDTX, AMPH, CALT, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CDTX Cidara Therapeutics	N/A	3.87	3.87
GPCR Structure Therapeutics	N/A	23.29	23.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
CALT Calliditas Therapeutics AB (publ)	2.83%
CDTX Cidara Therapeutics	35.82%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
CALT Calliditas Therapeutics AB (publ)	2.20%
CDTX Cidara Therapeutics	7.64%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.36 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	11.59 million	No Data
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable

CDTX, AMPH, CALT, and GPCR Headlines

Recent News About These Companies

Handelsbanken Fonder AB Buys 215,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

June 13, 2025 | marketbeat.com

Brokers Offer Predictions for GPCR FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.5% - Time to Sell?

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Estimates GPCR FY2025 Earnings

June 12, 2025 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.4% - Still a Buy?

June 11, 2025 | marketbeat.com

Equities Analysts Set Expectations for GPCR FY2026 Earnings

June 11, 2025 | marketbeat.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $76.50 Average Target Price from Analysts

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Predicts GPCR FY2025 Earnings

June 10, 2025 | marketbeat.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Makes New $3.09 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 3, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 29, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 4.6% - Here's Why

May 28, 2025 | marketbeat.com

Zimmer Partners LP Sells 154,200 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

May 23, 2025 | marketbeat.com

Vestal Point Capital LP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 21, 2025 | marketbeat.com

Wexford Capital LP Sells 16,351 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

May 21, 2025 | marketbeat.com

Tema Etfs LLC Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 20, 2025 | marketbeat.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Point72 Europe London LLP

May 18, 2025 | marketbeat.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

May 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, AMPH, CALT, and GPCR Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.34 -0.27 (-1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$25.34 0.00 (-0.02%)

As of 04:39 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 06/17/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cidara Therapeutics NASDAQ:CDTX

$21.31 -0.79 (-3.57%)

Closing price 04:00 PM Eastern

Extended Trading

$21.32 +0.02 (+0.07%)

As of 04:11 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Structure Therapeutics NASDAQ:GPCR

$21.62 +0.65 (+3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$21.60 -0.02 (-0.07%)

As of 04:04 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time